Stock Analysis, Dividends, Split History

EVOL / Evolving Systems, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price2.25
Volume17,300.00
Market Cap ($M)34.53
Enterprise Value ($M)34.09
Book Value ($M)34.61
Book Value / Share2.86
Price / Book0.79
NCAV ($M)3.82
NCAV / Share0.32
Price / NCAV7.14
Share Statistics
Common Stock Shares Outstanding 11,941,072
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 12,528,892
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.06
Return on Equity (ROE)0.09
Balance Sheet (mrq) ($M)
Assets55.90
Liabilities21.30
Quick Ration/a
Current Ratio1.47
Income Statement (mra) ($M)
Revenues28,812,000.00
Maintenance Revenue25,374,000.00
Discontinued Operations Unearned Revenue0.00
Contracts Revenue3,438,000.00
Number Of Revenue Types2.00
Number Of Sources Of Revenue2.00
Operating Income5.42
Net Income2.52
Earnings Per Share Diluted0.21
Earnings Per Share Basic0.21
Cash Flow Statement (mra) ($M)
Cash From Operations3.46
Cash from Investing-6.02
Cash from Financing-6.02
Identifiers and Descriptors
CUSIP30049R209
Central Index Key (CIK)1052054

Split History

Stock splits are used by Evolving Systems, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Evolving Systems' (EVOL) CEO Matthew Stecker on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Thank you and welcome to Evolving Systems 2018 Second Quarter Results Conference Call. As you may have seen, our Form 10-Q was filed after market close today, and our press release was just issued. (0-1)

Software company Evolving Systems fires CEO for cause - MarketWatch

2018-07-18 marketwatch
Evolving Systems Inc. EVOL, +2.83% said Wednesday it is removing Thomas Thekkethala, its chief executive and president, for cause and does not intend to pay him any severance. The company, which specializes in software for wireless operators, did not provide details. It said Matthew Stecker, who is currently chairman of the board, will become CEO with immediate effect. The company said it does not expect to change its outlook as a result of the firing, and that there were no disagreements with Thekkethala over any financial or accounting issue.

Evolving Systems' (EVOL) CEO Thomas Thekkethala on Q1 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to the Evolving Systems 2018 First Quarter Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session, and instructions for how to participate will follow at that time. [Operator Instructions] And as a reminder, this conference call is being recorded. (2-1)

Evolving Systems' (EVOL) CEO Thomas Thekkethala on Q4 2017 Results - Earnings Call Transcript

2018-04-04 seekingalpha
Good day, ladies and gentlemen, and welcome to the Evolving Systems 2017 Year-end Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct the question-and-answer session and instructions will follow at that time. [Operator Instructions] And as a reminder, this conference call is being recorded. (2-0)

CUSIP: 30049R209